214 related articles for article (PubMed ID: 28001152)
21. Development of a human three-dimensional organotypic skin-melanoma spheroid model for in vitro drug testing.
Vörsmann H; Groeber F; Walles H; Busch S; Beissert S; Walczak H; Kulms D
Cell Death Dis; 2013 Jul; 4(7):e719. PubMed ID: 23846221
[TBL] [Abstract][Full Text] [Related]
22. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
Trunzer K; Pavlick AC; Schuchter L; Gonzalez R; McArthur GA; Hutson TE; Moschos SJ; Flaherty KT; Kim KB; Weber JS; Hersey P; Long GV; Lawrence D; Ott PA; Amaravadi RK; Lewis KD; Puzanov I; Lo RS; Koehler A; Kockx M; Spleiss O; Schell-Steven A; Gilbert HN; Cockey L; Bollag G; Lee RJ; Joe AK; Sosman JA; Ribas A
J Clin Oncol; 2013 May; 31(14):1767-74. PubMed ID: 23569304
[TBL] [Abstract][Full Text] [Related]
23. Association between acquired resistance to PLX4032 (vemurafenib) and ATP-binding cassette transporter expression.
Michaelis M; Rothweiler F; Nerreter T; van Rikxoort M; Zehner R; Dirks WG; Wiese M; Cinatl J
BMC Res Notes; 2014 Oct; 7():710. PubMed ID: 25300205
[TBL] [Abstract][Full Text] [Related]
24. Prominent role of cyclic adenosine monophosphate signalling pathway in the sensitivity of (WT)BRAF/(WT)NRAS melanoma cells to vemurafenib.
Krayem M; Journe F; Wiedig M; Morandini R; Sales F; Awada A; Ghanem G
Eur J Cancer; 2014 May; 50(7):1310-20. PubMed ID: 24559688
[TBL] [Abstract][Full Text] [Related]
25. Spheroid Culture Differentially Affects Cancer Cell Sensitivity to Drugs in Melanoma and RCC Models.
Filipiak-Duliban A; Brodaczewska K; Kajdasz A; Kieda C
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163092
[TBL] [Abstract][Full Text] [Related]
26. Targeting melanoma stem cells with the Vitamin E derivative δ-tocotrienol.
Marzagalli M; Moretti RM; Messi E; Marelli MM; Fontana F; Anastasia A; Bani MR; Beretta G; Limonta P
Sci Rep; 2018 Jan; 8(1):587. PubMed ID: 29330434
[TBL] [Abstract][Full Text] [Related]
27. Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells.
Basile KJ; Abel EV; Aplin AE
Oncogene; 2012 May; 31(19):2471-9. PubMed ID: 21996740
[TBL] [Abstract][Full Text] [Related]
28. Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cells.
Faião-Flores F; Alves-Fernandes DK; Pennacchi PC; Sandri S; Vicente AL; Scapulatempo-Neto C; Vazquez VL; Reis RM; Chauhan J; Goding CR; Smalley KS; Maria-Engler SS
Oncogene; 2017 Mar; 36(13):1849-1861. PubMed ID: 27748762
[TBL] [Abstract][Full Text] [Related]
29. Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells.
Le K; Blomain ES; Rodeck U; Aplin AE
Pigment Cell Melanoma Res; 2013 Jul; 26(4):509-17. PubMed ID: 23490205
[TBL] [Abstract][Full Text] [Related]
30. Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032.
Søndergaard JN; Nazarian R; Wang Q; Guo D; Hsueh T; Mok S; Sazegar H; MacConaill LE; Barretina JG; Kehoe SM; Attar N; von Euw E; Zuckerman JE; Chmielowski B; Comin-Anduix B; Koya RC; Mischel PS; Lo RS; Ribas A
J Transl Med; 2010 Apr; 8():39. PubMed ID: 20406486
[TBL] [Abstract][Full Text] [Related]
31. Overcoming TRAIL-resistance by sensitizing prostate cancer 3D spheroids with taxanes.
Grayson KA; Jyotsana N; Ortiz-Otero N; King MR
PLoS One; 2021; 16(3):e0246733. PubMed ID: 33661931
[TBL] [Abstract][Full Text] [Related]
32. Design of human lactoferricin derived antitumor peptides-activity and specificity against malignant melanoma in 2D and 3D model studies.
Grissenberger S; Riedl S; Rinner B; Leber R; Zweytick D
Biochim Biophys Acta Biomembr; 2020 Aug; 1862(8):183264. PubMed ID: 32151609
[TBL] [Abstract][Full Text] [Related]
33. Differential effects of the oncogenic BRAF inhibitor PLX4032 (vemurafenib) and its progenitor PLX4720 on ABCB1 function.
Michaelis M; Rothweiler F; Nerreter T; Van Rikxoort M; Sharifi M; Wiese M; Ghafourian T; Cinatl J
J Pharm Pharm Sci; 2014; 17(1):154-68. PubMed ID: 24735766
[TBL] [Abstract][Full Text] [Related]
34. Tumor spheroid-based migration assays for evaluation of therapeutic agents.
Vinci M; Box C; Zimmermann M; Eccles SA
Methods Mol Biol; 2013; 986():253-66. PubMed ID: 23436417
[TBL] [Abstract][Full Text] [Related]
35. Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations.
Niehr F; von Euw E; Attar N; Guo D; Matsunaga D; Sazegar H; Ng C; Glaspy JA; Recio JA; Lo RS; Mischel PS; Comin-Anduix B; Ribas A
J Transl Med; 2011 May; 9():76. PubMed ID: 21609436
[TBL] [Abstract][Full Text] [Related]
36. The Combination of Vemurafenib and Procaspase-3 Activation Is Synergistic in Mutant BRAF Melanomas.
Peh J; Fan TM; Wycislo KL; Roth HS; Hergenrother PJ
Mol Cancer Ther; 2016 Aug; 15(8):1859-69. PubMed ID: 27297867
[TBL] [Abstract][Full Text] [Related]
37. In-air production of 3D co-culture tumor spheroid hydrogels for expedited drug screening.
Antunes J; Gaspar VM; Ferreira L; Monteiro M; Henrique R; Jerónimo C; Mano JF
Acta Biomater; 2019 Aug; 94():392-409. PubMed ID: 31200118
[TBL] [Abstract][Full Text] [Related]
38. A chondroitin sulfate proteoglycan 4‑specific monoclonal antibody inhibits melanoma cell invasion in a spheroid model.
Uranowska K; Samadaei M; Kalic T; Pinter M; Breiteneder H; Hafner C
Int J Oncol; 2021 Sep; 59(3):. PubMed ID: 34318902
[TBL] [Abstract][Full Text] [Related]
39. Establishment of Two Dimensional (2D) and Three-Dimensional (3D) Melanoma Primary Cultures as a Tool for In Vitro Drug Resistance Studies.
Cruz Rodríguez N; Lineros J; Rodríguez CS; Martínez LM; Rodríguez JA
Methods Mol Biol; 2019; 1913():119-131. PubMed ID: 30666602
[TBL] [Abstract][Full Text] [Related]
40. Impact of Collagen Triple Helix Structure on Melanoma Cell Invadopodia Formation and Matrix Degradation upon BRAF Inhibitor Treatment.
Shin DS; Schroeder ME; Anseth KS
Adv Healthc Mater; 2022 Apr; 11(7):e2101592. PubMed ID: 34783464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
